Is SABS or SANA more undervalued in 2026?

CirclFi compares SAB Biotherapeutics, Inc. (SABS) and Sana Biotechnology, Inc. (SANA) using 13 institutional-grade valuation models. SABS has a Quality of Company score of 5.0/10 while SANA scores 3.8/10.

Which is a better buy — SABS or SANA?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do SABS and SANA valuations compare?

SABS at $3.60 and SANA at $3.30 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

SABS vs SANA Valuation Comparison 2026 — Intrinsic Value Analysis

SABS

Biological Products, (No Diagnostic Substances)

SAB Biotherapeutics, Inc.

Quality

5.0

out of 10

Value Trap

WARN

Price

$3.60

Last close

Models

12/13

Active

SANA

Biological Products, (No Diagnostic Substances)

Sana Biotechnology, Inc.

Quality

3.8

out of 10

Value Trap

LOW

Price

$3.30

Last close

Models

7/13

Active

Model-by-Model Comparison

Model	Type	SABS Fair Value	SABS Upside	SANA Fair Value	SANA Upside
Bayesian DCF	Intrinsic	$1.27	-64.8%	$0.87	-73.6%
Earnings Power Value	Intrinsic	$6.17	+77.9%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$2.73	-28.3%	$0.85	-74.3%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for SABS vs SANA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

SABS vs SANA — Which Stock Is More Undervalued?

SABS scores higher with a 5.0/10 quality rating vs SANA's 3.8/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing SAB Biotherapeutics, Inc. (SABS) and Sana Biotechnology, Inc. (SANA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

SABS currently trades at $3.60 with a QOC of 5.0/10, while SANA trades at $3.30 with a QOC of 3.8/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).